Jump to navigation

  • IHME
  • GHDx
  • GBD Compare
Home
Main menu
  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
      • IHME Foundations
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Murray-Lopez Award
    • Online Training
    • Courses
    • Degree programs
    • Workshops
  • About
    • Racism is a public health issue.
    • Our Principles
    • Faculty
    • Senior Management Team
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Explore section

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Acute hepatitis — Level 3 cause


Summary Acute hepatitis resulted in 4·35 million (95% UI 3·57–5·22) global DALYs in 2019. Acute hepatitis A, B, C, and E contributed 53·9% (42·9–63·6), 37·2% (27·8–47·4), 5·8% (3·4–8·8), and 3·0% (2·1–4·0) to DALYs for the acute hepatitis parent, respectively.

Definition Hepatitis is a viral infection that can lead to inflammation of the liver. This Level 3 cause incorporates death and disability resulting from acute hepatitis A, B, C, and E.

Total sources
Incidence 0
Prevalence 1199
Remission 0
Causes of death 3837
Other 32
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •Adjustments for seroprevalence data from blood donors and pregnant women were estimated in MR-BRT relative to seroprevalence data among the general population.
  • •The results of the DisMod-MR model of hepatitis B surface antigen prevalence at younger ages were adjusted downward, reflecting coverage and efficacy of vaccination by country and year.
  • •Analysis conducted in MR-BRT using 42 studies that reported on the prevalence of anti-HCV antibody and HCV-RNA produced a pooled estimate of proportion viremic among the seropositive individuals to correct outputs of our model of anti-HCV seropositivity to estimate viremia.
  • •Mortality due to acute hepatitis A, B, C, and E was modelled in CODEm rather than in the natural history models used in past GBD rounds which required case fatality from hospital inpatient data.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
23·6
(21·5
to 25·8)
319·5
(293·2
to 347·5)
264
(244
to 285)
3615·9
(3360·5
to 3888·3)
0·0792
(0·0658
to 0·0953)
1·0
(0·8
to 1·2)
3·93
(3·16
to 4·84)
52·6
(42·0
to 65·1)
0·414
(0·266
to 0·608)
5·4
(3·4
to 7·9)
4·35
(3·57
to 5·22)
58·0
(47·3
to 70·0)
Females
10·6
(9·66
to 11·7)
294·7
(270·1
to 322·8)
121
(112
to 131)
3400·2
(3152·2
to 3666·9)
0·0330
(0·0274
to 0·0432)
0·8
(0·7
to 1·1)
1·66
(1·34
to 2·22)
45·5
(36·4
to 60·9)
0·185
(0·118
to 0·271)
4·9
(3·1
to 7·1)
1·85
(1·51
to 2·41)
50·4
(40·7
to 66·2)
Males
13·0
(11·7
to 14·5)
344·4
(311·1
to 382·0)
143
(131
to 157)
3832·2
(3509·2
to 4167·8)
0·0462
(0·0361
to 0·0561)
1·2
(0·9
to 1·5)
2·27
(1·72
to 2·79)
59·7
(45·0
to 73·7)
0·228
(0·146
to 0·336)
5·8
(3·7
to 8·6)
2·50
(1·94
to 2·99)
65·6
(50·7
to 79·1)
Percentage change 2010-19
Both Sexes
–2·0%
(–8·9
to 5·4)
–8·1%
(–14·3
to –1·8)
–0·8%
(–6·3
to 5·2)
–6·4%
(–11·3
to –1·4)
–27·8%
(–39·6
to –10·7)
–36·9%
(–47·3
to –21·7)
–38·2%
(–50·1
to –22·2)
–43·6%
(–54·7
to –28·9)
3·7%
(–5·4
to 13·0)
–4·9%
(–13·2
to 3·6)
–35·7%
(–47·0
to –21·0)
–41·4%
(–52·2
to –27·7)
Females
–1·4%
(–9·4
to 7·4)
–7·2%
(–14·2
to 0·3)
–0·2%
(–6·5
to 6·5)
–5·6%
(–11·1
to 0·1)
–34·4%
(–44·7
to –10·2)
–43·1%
(–52·5
to –21·7)
–45·1%
(–55·8
to –23·6)
–49·9%
(–60·2
to –29·9)
4·1%
(–7·4
to 16·2)
–4·1%
(–14·7
to 7·1)
–42·3%
(–52·6
to –21·8)
–47·5%
(–57·5
to –28·7)
Males
–2·5%
(–12·4
to 8·2)
–8·8%
(–17·5
to 0·8)
–1·2%
(–9·2
to 7·3)
–7·0%
(–14·4
to 0·5)
–22·1%
(–38·6
to –4·6)
–31·7%
(–46·5
to –16·3)
–32·0%
(–48·3
to –15·3)
–37·8%
(–52·9
to –22·4)
3·4%
(–9·0
to 17·1)
–5·5%
(–16·8
to 7·1)
–29·8%
(–45·1
to –14·2)
–35·8%
(–50·1
to –21·3)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 44th 35th 100th 54th
2010 64th 49th 103rd 72nd
2019 79th 64th 107th 91st
Table 3: Rank among Level 3 causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by constituent Level 4 causes for both sexes combined, 2019
Figure 2: Percentage of DALYs attributable to top risk factors for both sexes combined, 2019
No Legend
Figure 3: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 4: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 5: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Stay connected

     

IHME

Institute for Health Metrics and Evaluation

Population Health Building/Hans Rosling Center

3980 15th Ave. NE, Seattle, WA 98195

UW Campus Box #351615

Tel: +1-206-897-2800

Fax: +1-206-897-2899

© 2020 University of Washington

  • Privacy policy
  • Login

  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Murray-Lopez Award
    • Online Training
    • Courses
    • Degree programs
    • Workshops
  • About
    • Racism is a public health issue.
    • Our Principles
    • Faculty
    • Senior Management Team
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Projects

  • Global Burden of Disease (GBD)
  • Disease Control Priorities Network (DCPN)
  • ABCE+: A Focus on Antiretroviral Therapy (ART)
  • Access, Bottlenecks, Costs, and Equity (ABCE)
  • Efficacy to Effectiveness
  • Viral Load Pilot
  • Salud Mesoamérica Initiative
  • Improving Methods to Measure Comparable Mortality by Cause
  • Verbal Autopsy (VA)
  • Disease Expenditure (DEX)
  • Local Burden of Disease
  • State-level disease burden initiative in India
  • US Counties Drivers of Health Study
  • University of Washington Center for Health Trends and Forecasts